DYRK1A and diabetes mellitus: According to current knowledge, DYRK1A and DYRK1B appear to act similarly in cell cycle control and pharmacological DYRK1 blockade might thus be exploited to expand pancreatic β-cell pools in the fight against diabetes [62–64] (Fig. 1).